For a dentist hunched over a molar or a surgeon working a narrow operative field, the workday begins with a pair of optical loupes clipped to a frame. The magnification is fixed, the working distance is fixed, and the neck pays the price. NuEyes, a small hardware company in Newport Beach, thinks the next pair of loupes a clinician buys will be a headset with two cameras, variable digital magnification, and a live 3D feed of the patient's anatomy. Its product, NuLoupes, received FDA Class I 510(k) exemption in December 2023 [SAGES, Dec 2023], clearing the regulatory hurdle that any visualization device must clear before it can sit on a clinician's face inside an operatory.
The patient population NuEyes is implicitly serving is broad: anyone undergoing a procedure where the operator's depth perception, posture, and ability to share a view with the rest of the care team affects the outcome. That includes restorative and surgical dentistry, oral surgery, and a range of minimally invasive general surgery cases where standard 2.5x to 4.5x optical loupes are the norm. The standard of care today is unglamorous and durable. Most clinicians work with custom-fit Galilean or prismatic loupes from vendors such as Orascoptic, Designs for Vision, or SurgiTel, paired with a headlamp. Magnification is set at purchase, the field of view is small, and ergonomic strain is a well-documented occupational issue, particularly in dentistry. Digital alternatives exist, but adoption has been slow because clinicians are conservative about anything that sits between their eyes and the patient.
The bet
NuEyes is selling a digital AR headset purpose-built for that workflow. NuLoupes uses a dual 3D camera system with a reported 5 to 6 inches of depth of field [Forbes, Apr 2023], offers high-resolution variable digital magnification [Access Newswire], and delivers what the company describes as live 3D stereoscopic imaging with near-zero latency and submillimeter depth perception [DrBicuspid]. The headset also lets clinicians recognize objects, live stream the operative view, and pull up patient data in the same field of vision [Dental Products Report]. The device is patent-pending [Yahoo Finance, Dec 2023] and was developed with input from practicing surgeons and dentists [Newswire]. A full market launch is planned for late 2025 [Whitefield BioMed].
The wedge is regulatory and ergonomic rather than algorithmic. NuEyes is not pitching a diagnostic AI that needs its own clinical trial. It is pitching a visualization device that sits inside the Class I exempt pathway, which means the FDA has agreed the risk profile does not require premarket notification. That is the correct lane for a first product in this category, and it is the same lane occupied by traditional surgical loupes and headlights.
The tailwinds
The tailwinds are real. Dentists retire early from musculoskeletal injury at rates that have been documented for decades, and any device that lets a clinician sit upright while still seeing a magnified field has a clear ergonomic case. Live streaming and shared views matter for training, for tele-mentoring, and for documentation in an era where payers and malpractice carriers increasingly want a record. The competitive set is small. Vuzix sells smart glasses into enterprise and medical channels, but its devices are general-purpose. Purpose-built surgical AR has been attempted by larger players, including Augmedics in spine and various Microsoft HoloLens 2 deployments, but the dentistry-and-general-surgery loupe replacement slot is still wide open.
NuEyes has been backed by Openner, Arab Angel, and Seed Group, and went through StartUp Health, the digital-health accelerator that has historically taken long-cycle bets on hardware and devices. Total disclosed outside funding is small, around $22,800 across a seed and a 2017 early-stage round, and founder Mark Greget has said publicly that the company has been bootstrapped [AR Show Podcast]. That is unusual for a hardware company chasing a regulated market, and it cuts both ways: it has kept the cap table clean and the burn low through a multi-year FDA process, but it leaves limited capital for a sales motion into dental practices and hospital procurement.
| Milestone | Date |
|---|---|
| Company founded | 2016 |
| Early-stage round closed | Jun 2017 |
| FDA Class I 510(k) exemption for NuLoupes | Dec 2023 |
| Planned full market launch | Late 2025 |
The team
Mark Greget, a U.S. Navy veteran, is founder and CEO and developed NuLoupes in response to needs he saw in surgical visualization [NuEyes]. Fraser Bowie serves as Chief Product Officer [Forbes, Apr 2023]. Mark Kelley, who joined the board of advisors and is described as the visionary behind the NuLoupes industrial design, also serves as Creative Director [LinkedIn]. The company's earlier product line focused on AR/VR aids for patients with macular degeneration, achromatopsia, and congenital nystagmus [Patient Worthy, Jun 2019], which gave the team several years of experience shipping head-worn optics into a clinical context before pivoting toward the operator-facing surgical product.
The honest counterfactual
The bear case is straightforward. Clinicians have bought optical loupes the same way for thirty years, and convincing a dentist to swap a $1,500 pair of Designs for Vision loupes for a digital headset will require both clinical evidence and a financing model that fits a private practice's budget. Vuzix and other AR hardware vendors have larger balance sheets and existing enterprise channels [company materials]. The bull answer is that the FDA clearance is in hand, the SAGES technology assessment has put the device in front of practicing surgeons [SAGES, Dec 2023], and the category of digital loupes has very few purpose-built entrants. A small, focused company that owns the clinical use case can move faster than a general-purpose AR vendor that has to split attention between warehouse picking, field service, and the operating room.
What to watch
The next twelve months will turn on three things: the late-2025 commercial launch and whether NuEyes ships at the volumes its dental and surgical pilot users expect, the publication of any peer-reviewed clinical evaluation beyond the SAGES assessment, and whether the company raises a priced round to fund a real sales organization. A bootstrapped hardware company with an FDA-cleared device is a rare profile, and it tends to attract strategic interest from larger dental and surgical distributors. The patient on the table will not know whether the operator is wearing glass or silicon. What matters is whether the operator can see better, sit straighter, and share the view. That is the outcome NuEyes has to prove.
Pulse Raman, Health and Bio Correspondent.